The WHO Independent Panel of Experts recommends the use of Sinovac vaccine for people over 18 years of age. The evaluation data show that this vaccine is effective in protection in the elderly. Sinovac is the second Chinese vaccine approved by WHO for emergency use. (Photo: Reuters) WHO’s decision was made based on a review of the latest clinical data on the safety and efficacy of Sinovac’s vaccine as well as the company’s manufacturing practices. On May 5, the WHO technical advisory group met, reviewed and evaluated the Sinovac vaccine. WHO Director-General Tedros Adhanom Ghebreyesus said that Sinovac vaccine is safe and effective, emphasizing that it does not require a high level of vaccine preservation, suitable for low-income countries. “Now it’s important to get these life-saving tools quickly into the hands of those who need them.” , the head of WHO said. Sinovac is the second Chinese vaccine approved by WHO for emergency use. On May 7, the Sinopharm vaccine became the first vaccine not from a Western pharmaceutical company to be approved by the WHO. Meanwhile, China’s third vaccine, manufactured by CanSino Biologics, has also submitted clinical trial data. However, WHO has not yet scheduled an assessment. As of the end of May, Sinovac pharmaceutical company has supplied more than 600 million doses inside and outside China, of which more than 430 million doses have been used.

COVAX-19 mechanism. (Artwork: ABC News) In 2020, the Mechanism of “Global Access to Vaccines Against Covid-19” (COVAX for short) was established to help all countries have the opportunity to have quick, equitable and equal access to vaccines. prevent Covid-19. However, the goals of the above initiative are being “missed” due to lack of capital and selfishness of some developed countries. Launched in 2020, COVAX aims to buy two billion doses of vaccine to distribute to countries supporting the fight against Covid-19 before the end of 2021. However, the above ambitious plan is at risk of bankruptcy when Statistics show that, so far, only 68 million doses of vaccine from COVAX have been delivered, reaching 3.4% of the plan. Meanwhile, by the end of May 2021, there were 1.5 billion doses of Covid-19 vaccine distributed worldwide, but only about 0.3% of them reached countries with low income. low input. World health experts point out that the disappointing results mentioned above are not due to the lack of efforts by the people in charge of the COVAX program of the World Health Organization (WHO), but mainly due to a lack of funding. There is a shortage of vaccine supplies, and rich countries are unwilling to share vaccines with poor countries. COVAX is intended to be a not-for-profit financial attraction structure. Accordingly, rich countries contribute financially to research many different vaccines at the same time to find some effective vaccines, and then provide them for free to 92 low-income countries who cannot afford to buy them. vaccine against Covid-19. For this mechanism to work, there needs to be enough rich countries to invest and commit to receive vaccines through COVAX. However, in reality, this initiative did not receive the necessary funds to support research and purchase the vaccine in the early stages. Even, many rich countries have signed contracts to buy vaccines individually with manufacturers such as Pfizer, Moderna, delaying the implementation of contracts for large-scale production of vaccines in 2021 under the COVAX mechanism. A major problem hindering COVAX’s vaccine supply efforts is the tight supply of vaccines. Part of the reason for this is the serious epidemic situation in India. The main vaccine supplier for COVAX is the Serum Institute of India, which is producing the AstraZeneca vaccine. However, with the outbreak of the disease, the planned supply of vaccine for COVAX had to be diverted to serve India’s domestic demand. WHO and the Global Vaccine Alliance Gavi, representing the organizations initiating the COVAX Mechanism, have just issued a statement stating that an additional $2 billion is needed to increase the coverage of immunization programs to nearly 30 million. %. To secure vaccine delivery this year and early 2022, COVAX needs the above amount before June 2 to close the supply. According to the original target, COVAX is expected to provide two billion doses of vaccine to countries in 2021 and 1.8 billion doses in early 2022. “Financial bottlenecks” are hindering goals and efforts COVAX’s vaccine delivery force. COVAX initiative managers also warn that, if the current emergency shortage of a Covid-19 vaccine is not addressed, “the consequences could be dire.” The above fact shows that COVAX’s “vaccine for everyone” and “leave no country behind” plan are being delayed. This is not only a problem of COVAX founders and managers, but a big global problem. Because, variants of this virus and new waves of epidemics can enter and re-emerge in developed countries at any time. The only way for humanity to win the current pandemic together is for governments and people of countries, especially developed countries, to share difficulties, distribute vaccines appropriately, and join hands to fight Covid-19.

The effectiveness of the vaccine so far cannot be denied. The United States, although not widely open to the world, has dragged down its number of infections in just the past few months. Based on data collected during vaccination, the US Centers for Disease Control and Prevention (CDC) has announced that the effectiveness of major vaccines such as Pfizer or Moderna is up to 95%. even with new variants. This makes it possible for American people to comfortably go out without having to wear a mask, while the US Government considers lifting the ban on international movement. Similar effects have also been observed in Israel and Europe, where vaccination rates have reached 60% – that is, herd immunity can be generated. The “miracle” that brought life back to its normal rhythm seemed to be at last. Small doses of vaccines are becoming the hope of the whole world in the fight against COVID. However, at the same time, a new wave of infections broke out in India. Since mid-April, an additional 5 million new infections have been recorded in this South Asian country. The number of new infections continuously reached approximately 300 thousand cases per day, of which several thousand people died from the disease every day. The epidemic tsunami was so great that it knocked down India’s health system in just a few days, a real disaster. It is hard to believe, until the 4th wave of infections broke out, India was the country with the 3rd highest number of COVID vaccines in the world and was a hope for the whole world thanks to its huge vaccine supply. However, the number of nearly 100 million doses of vaccine administered out of a population of 1.3 billion is still too small to achieve a state of herd immunity, as epidemiologists hope. The government’s subjectivity then caused the contagion to erupt violently at a time when major religious ceremonies were held in this huge country. Consequences for the people and country of India so far have not been fully enumerated, but more dangerous, it is slowing down the whole world’s efforts to open up, when the supply of vaccines is mainly for people. Poor countries under the WHO COVAX program have stalled, because India has urgently applied a ban on vaccine exports to save itself first. In addition, the fourth wave of infections has also begun to spread around the world, from Asia, Africa to South America, where vaccination rates are far from reaching the thresholds that can create health problems. herd immunity. No one can stand alone The Indians cannot be blamed for the decision to close the vaccine supply at this time, because indeed the images and death figures every day in the newspaper make anyone horrified. Before that, it was India that took the lead in efforts to help the poorer people to have access to 66 million doses of vaccine in the first quarter of this year. Now that responsibility needs to be reinforced. In contrast, the US, UK, EU and Israel have come up with plans to reopen. Learning from India’s mistakes, these countries have been more cautious. From May 23, tourists can return to Israel and the EU if they comply with the mandatory conditions. The problem is that if that rule is followed, there are not many qualified guests. Because, in addition to having received the correct vaccines recognized by the EU, that traveler must also be from countries with the number of new infections below 25 cases per 100,000 inhabitants in the previous 14 days. Those are the countries that the EU calls “safe”. However, there are currently only 7 countries outside the EU that meet this criterion, such as Israel, Australia, New Zealand, Singapore, etc., but that list does not include the US. That is, the invitation to travel to Europe is still only “give it up”. The door was opened but very few people could enter. The “Indian lesson” makes us realize that vaccination speed will determine the success or failure of a global vaccine strategy. As the United States and Israel quickly immunized the majority of the population, the SARS-CoV-2 virus was easily defeated. But, the drip vaccination rate will not be enough to create herd immunity and even allow the virus to mutate against the same old vaccines. Finding a vaccine for the poor is never easy. The fourth wave of contagion, therefore, has broken out in these very countries, with new variants that are more dangerous and could completely hit countries that already have high vaccination rates. Therefore, in order to solve the problem at the root, it is the rich countries that will have to take the lead in a new effort, to rescue the worldwide shortage of vaccines. Conflicts of interest A group of 13 countries has been identified by the World Bank (WB) as holding control and global distribution of vaccines. Among these, there are of course big countries like India, China, Russia, the G7 group and a few other European countries like Austria, Switzerland, Sweden. They are collectively known with a beautiful name, “The Club of Vaccine Producing Countries”. This club controls up to 88% of vaccines and 91% of vaccine companies in the world. Among them, mainly developed countries in the West. It is not surprising that the US and EU have achieved the highest vaccination rates in the world in a short time. Despite earlier claims to share vaccines with the world, “vaccine nationalism” prevailed initially. They have even started to have an oversupply of vaccine in their inventory after the last 3 months of intense vaccination. Therefore, when making the call for the rescue of vaccines in the world, both WHO and the United Nations are directly targeting this group of countries. Now it’s time for them to extend their hand to play the role of “saving the world”. However, this is also the time when the controversy broke out the most. The US has announced that it will deliver 70 million doses of its vaccine to developing countries between now and July. The EU will also contribute back to the COVAX program, after a temporary withdrawal to keep the vaccine for itself. But, even so, it’s still not enough. Because the most advanced vaccines being used by the US and EU require extremely complex preservation technologies that are not easy for poor or developing countries to meet. In Africa, hundreds of thousands of doses of vaccines have been destroyed, even though they still have their expiry date, because they cannot guarantee the storage conditions on the way to users. This situation may be even more serious, when the number of vaccines from the EU and the US is brought in in large numbers in the near future. And the cost of high-end vaccines like Pfizer or Moderna is never cheap, when Pfizer – BioNtech or Moderna apply the most advanced technologies that not even Russia or China have access to. A new call has been made, for rich countries to share vaccine copyrights with poor countries, in order to create a vaccine that suits them. However, advanced genetic technologies are copyrighted by major pharmaceutical companies, where they want to hold the secret not only for this COVID vaccine. As a result, the controversy has shifted from the states to the people of the vaccine-hungry poor countries, with the wealthy owners of the big pharmaceutical companies. Loss of motivation to research to find new products is the reason that big pharmaceutical companies rely on to protect their patents. Meanwhile, inequality in vaccine distribution has serious consequences for the lives of hundreds of millions of other people. Still, it wasn’t easy for those wealthy owners to give in. Therefore, before relying on the “kindness” of pharmaceutical companies, the most concrete thing that rich countries can do is probably just to try to fill this inequality by giving poor countries the opportunity to do so. access to their starting surplus vaccine resources. Saving people is actually saving yourself.
Tu Uyen

Russia has developed a project to build a patrol boat capable of diving. Such a ship combines the main features and advantages of a submarine and a surface patrol vessel. The project is intended for export and is supposed to attract the interest of less affluent countries looking to upgrade their fleets. In mid-April 2021, Rubin Design Studio unveiled a new project. They provide background information about an unusual idea, upcoming implementation, and expected results. In addition, this design studio also shows a hologram of a patrol boat with submarine features. The new export-oriented project is named ‘Sentinel’ in Russian, with the English designation chosen as ‘Border and Offshore Submersible Sentry’ or ‘BOSS’ . Sentinel will most likely be marketed as ‘BOSS’ in the international market. The project developers note that modern patrol boats are relatively cheap – and due to their low cost, they attract the attention of poor countries. The main goal of such ships is to be able to prevent poaching and illegal fishing. “Project Sentinel proposes the construction of a ship capable of operating on water or under water. It is claimed that such a ship in a position on the water will be able to carry out official patrols, locate and arrest violators,” said Viktor Murahovsky, editor-in-chief of the magazine’ Homeland Arsenal’, said. “The underwater location is intended for covert surveillance of intruders, reconnaissance and even to avoid adverse weather conditions.” According to him, this is the first version of the diving patrol boat. In the future, the model can be modified to suit the wishes of foreign customers. The official image shows a ship that has the appearance of a submarine but has some uncharacteristic features of a submarine. The Sentinel had an elongated hull with a flat deck on which a limited-sized superstructure was placed. At the bow of the ship, the shield of the hydroacoustic complex antenna can be seen. On either side, forward of the superstructure control tower, there are extendable horizontal rudders. At the stern of the ship there is a compartment for storing motorboats that are brought on deck. As expected, the architecture and main dimensions of the ‘Sentinel’ are similar to the diesel-electric submarines designed under the old ‘Project 613’. This is a major project in the history of the Russian Navy and is very popular with foreign customers. Depending on configuration, ‘BOSS’ ships can be up to 60-70 meters in length and displace around 1,000 tons – approximately the size of an average 613 submarine. The full composition of the ship’s special systems and equipment is not specified. But this semi-submersible patrol boat is capable of carrying weapons of all kinds. It can be equipped with a small artillery complex, a missile system or torpedoes. For reconnaissance and inspection of other ships, the ship will be able to carry UAVs and motorboats. Sentinel can accommodate up to 42 people. This includes crew members, ship operators, and inspection teams responsible for dealing with violators. “The development of the Sentinel project is to meet the current requirements of the international market. Many countries are expressing interest in patrol boats. Thanks to the Sentinel project, Russian industry was able to gain a new position in the international market,” said expert Murahovsky.

Nigeria will become the next big Covid-19 “outbreak” after India. (Source: Anadolu Agency/Getty) And experts are cautiously observing a developing country, with a large area, disparities in health services and unequal access to vaccines, like India, that is Nigeria. With 200 million people, it is the most populous country in West Africa and the 7th most populous country in the world. Ngozi Erondui, a senior research fellow at the Chatham House Center for Global Health Security in the UK, said that “Nigeria is really vulnerable” and “has a lot in common with India”. When rich countries are not willing to share The world will not be able to do anything to prevent Covid-19 from ravaging Nigeria like the situation is happening in the past days in India. A more equitable distribution of vaccines could build a “firewall” against the rise in infections in Nigeria, as well as in other less developed countries. However, that will require the more economically developed countries of the world to share rescue resources with poorer countries. The tragic case of India proves that the vaccine-rich country in the world will not be in a hurry to help poor countries on distant continents. In fact, Africa is not necessarily synonymous with “poverty”. The continent is huge and diverse, comprising 54 countries with 1.2 billion people running economies from large to small, rich to poor, strong to weak. Likewise, African countries’ pandemic experiences vary widely. South Africa, one of the wealthiest countries on the continent, was hit hard last summer and then returned in January. Officials in the region recorded more than 54,000 deaths. The mortality rate is 93 deaths per 100,000 population, a number far below the US 175 deaths per 100,000 population, but much higher than the global average of 38 deaths. per 100,000 inhabitants. So far, many less industrialized African countries have avoided catastrophic spikes in infections, recording fewer deaths than rich countries. A total of 580,000 Americans have died from Covid-19 while only 1,600 Nigerians have died from the pandemic. SARS-CoV-2 virus – “opportunistic” virus However, that doesn’t mean Covid-19 won’t reach Nigeria and other African countries, it just means it hasn’t arrived yet. Lawrence Gostin, a global health expert at Georgetown University, told T he Daily Beast : “I am seeing the possibility that the Covid-19 fires will ravage around the world in the weeks and months to come. And I’m most worried about Africa.” According to Mr. Gostin, “the crisis in India is a leading indicator of what is to come in other low- and middle-income countries”. Despite its crowded cities, limited public health measures and a patchwork health care system, India has so far been considered relatively fortunate. The South Asian country has 1.37 billion people but only 160,000 deaths so far in March, with a rate of 11 deaths per 100,000 inhabitants. Then, in April, a new and more contagious variant of the SARS-CoV-2 virus, known as B.1.617, emerged and spread across India, causing a record increase in cases and deaths. green. In just a few weeks, India had nearly 50,000 more deaths. The death rate rose to 15 per 100,000 population. When this article was published, the Covid-19 wave in India was underway, but the trend was already decreasing. The rate of new cases and deaths is decreasing. And while it is predicted that tens of thousands of more Indians will die before this spike is over, at least the pandemic has not gotten any worse in the country. But the SARS-CoV-2 virus is an opportunistic virus. It always finds places that are densely populated but have no protection. Spreading through the air from person to person, Covid-19 establishes a “laboratory” in each body that the virus infects. Each SARS-CoV-2 virus mutates after two weeks of infection for as long as it is active, and seeks to evolve so that it can create a new variant that is increasingly contagious. New variants help the virus spread even faster in a self-reinforcing cycle that ends only with drastic social distancing, vaccinations and antibodies among survivors, or more likely a combination of the virus. all three methods to cut off the transmission route of Covid-19. It is no coincidence that SARS-CoV-2 thrived in India this month. Popular religious festivals have attracted thousands of people who attended without wearing masks. Meanwhile, India’s vaccination effort is very bad. According to statistics, the South Asian country has fully vaccinated only 3% of the population, compared with more than 30% in the US. The global average for full immunization is also a little over 3%. From the epidemiologist’s point of view, Nigeria, with its many overcrowded cities, high poverty rates and shabby health system, is quite similar to India, but worse in some respects. India has at least some domestic vaccine manufacturers, while Nigeria has none. The African country must import all doses of the vaccine from outside. That explains why Nigeria only partially immunizes 1% of the population and almost no one is fully vaccinated. The Lagos government is expected to receive 84 million doses of the vaccine from AstraZeneca and Johnson&Johnson in the coming weeks. But that number is only enough to inject a fifth of the country’s population. Meanwhile, the proportion that experts say could lead to “herd immunity” is vaccination of three-quarters of the population, which blocks most routes of transmission and can last up to year 2022. Shortage side, surplus side To help Nigeria and the underserved countries, the rich countries of the world should stop hoarding vaccines excessively. Of course, more shots are not a panacea, and even a country with many vaccines can have trouble administering. However, the vaccine shortage, and the hesitation among people who doubt the vaccine’s effectiveness, could further slow the vaccination process. Shaun Truelove, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health, said that “the only way to know if Nigeria is managing vaccines well is to keep shipping the vaccine to the country”. Global supply is not the biggest problem. The United States, a country with many vaccine manufacturers, has a stockpile of more than 60 million doses of vaccine while continuing to have more vaccines supplied by factories, while vaccination rates are falling. especially for Republicans. It was only a few weeks after the sudden spike in Covid-19 in India that the administration of President Joe Biden promised to ship an additional number of vaccines to New Delhi. The AstraZeneca vaccine isn’t even authorized in the US. For Americans, those doses of vaccines are not only redundant but also useless. The problem of severe delays in the release of excess vaccines was anticipated a year ago. In the spring of 2020, the World Health Organization (WHO) together with a number of international public-private partners, came together to establish the Global Access to Vaccines Covid-19 initiative, or COVAX. The COVAX initiative allows rich countries to pay for vaccines to poor countries. COVAX’s goal was to deliver 100 million doses by March, but it actually delivered less than 40 million doses. “This has failed Nigeria and many countries,” Mr. Erondu said [trong việc tiêm chủng]”. America is part of the problem. The Trump administration has refused to sign on to COVAX, a move that reflects its narrow “America First” philosophy. The Trump administration at the time either didn’t understand, or didn’t care, that vaccinating poor countries also helped protect rich countries. After all, the virus doesn’t care about borders. Mr. Biden reversed the decision in February. The administration has committed $4 billion in cash, making the US the largest donor of COVAX, albeit somewhat belatedly. In a parallel move, Mr. Biden also signaled support for a controversial proposal to give the WTO a copyright exemption for a Covid-19 vaccine. In theory, the decision would allow any manufacturer in any country to produce doses of the vaccine. However, experts are still divided on whether the patent waiver will lead to more doses of the vaccine being shipped to countries in need. Meanwhile, many richer countries have been slow to implement their COVAX commitments. Meanwhile, strains of the SARS-CoV-2 virus continue to target unprotected populations from one area to another. Nigeria is about to become the “storm center” of Covid-19. However, this West African country may not suffer the same fate as India. Because vaccines are available. Existing mechanisms will get the vaccine to the countries that need it most. It is worth mentioning that many countries have a surplus of vaccines but do not appreciate the importance of sharing vaccines with other countries. (According to Daily Beast)

This has resulted in many countries that used to order large quantities of vaccines, but were unable to use them. And the liquidation of excess vaccine doses is becoming a new problem that causes these countries to “headache”. What is really happening According to the BBC, the cause comes from concerns about rare, and sometimes fatal, cases of blood clotting abnormality, after receiving even one dose of the AZ and J&J vaccines. . This concern is growing, especially among young people. The excess amount of Covid-19 vaccine is causing many countries to “headache”. Photo: AP Based on data from the British Drug Administration, for every 10 million people assumed to be vaccinated with the AZ vaccine, about 40 people develop abnormal blood clots, of which 10 are at risk of death. This proportion equates to the risk of dying from homicides or road accidents in the UK in 2018. That is why the Danish health authority decided to stop using the AZ vaccine in response to the “risk of serious side effects”. This decision means that the 2.4 million doses of unused AZ vaccine in Denmark are at risk of being recalled. South Africa also suspended the distribution of the vaccine, as it was found to be less effective against strains. The same goes for J&J’s single-dose Covid-19 vaccine. Until safety investigation and testing is completed, the vaccine will not be approved for use in the US, which has 100 million pre-ordered doses. Number of ‘in stock’ vaccines Although there are no global overview data, individual country data can provide an overview of the current status of vaccine oversupply. According to data from the Centers for Disease Control and Prevention (CDC), an average of more than 20% of vaccines in the United States are unused. However, some states also exceed this rate such as Alabama (37%), Alaska (35%), Vermont (27%) and North Carolina (24%). Similar circumstances are playing out in Europe, where several countries have enacted restrictions on AZ and J&J vaccination against older adults. Data from the European Center for Disease Control and Prevention (ECDP) shows that out of a total of 202,920 doses of new AZ vaccine received by Denmark on April 15, 150,671 doses were distributed for vaccination. Danish medical director Soeren Brostroem said the AZ vaccine recall was a “difficult” decision. Photo: EPA Find a liquidation solution In theory, countries can still sell or donate vaccines they no longer use to other countries. On April 15, Hans Kluge, European Director of the World Health Organization (WHO), said that Denmark is looking to do this. “I understand that the Danish Ministry of Foreign Affairs is ready or considering options to share the AstraZeneca vaccine with poorer countries,” Kluge said at a news conference. In the opposite direction, many neighboring countries with Denmark also offered to buy back. Prime Minister Ingrida Simonyte has offered to be ready to receive a large number of AZ vaccines with Denmark. Czech Interior Minister Jan Hamacek also said that he had instructed a diplomat to declare the country’s interest in “buying all AZ vaccines from Denmark”. However, Copenhagen has yet to comment or respond to these requests. In the meantime, the vaccines are still stored in cold storage without an appointment for use. Share to the world Currently, Covax is considered the most feasible way for many countries to distribute their surplus vaccines to the world. With a mission to share vaccines fairly between countries, regardless of rich and poor, Covax aims to deliver more than 2 billion doses to people in 190 countries by the end of 2021. Photo: Reuters Some developed countries also plan to distribute their own excess vaccines. For example, the UK, which owns about 450 million doses of vaccine, has pledged to fund most of the “surplus” vaccine source to poorer countries. More than 1 million doses of the AZ vaccine recalled by South Africa were distributed to 14 other African countries. While it is not yet specific when or how many doses of vaccine will be distributed, this suggests that at least for now, developed countries still have a responsibility to share excess vaccine. to the world, through programs like Covax. In response to the BBC, the representative of the Global Alliance on Vaccines and Immunization said: “With a limited supply of vaccines in the near future, doses of vaccines are donated from other countries. Surplus and equitable allocation through Covax will be the key solution, for equitable and rapid access to vaccines globally. We are talking to some high-income economies about their share of excess vaccines, and expect them to announce the deals soon. ” Vietnamese-English